Model‐Informed Drug Development Supports Full Approval of Ibuprofen Injection in Chinese Pediatric Patients With Fever or Pain
Clinical Pharmacology & Therapeutics · 2026
DOI: 10.1002/cpt.70143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Qianxi Lou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shando…. Hauptthemen laut MEDLINE: Ibuprofen, Anti-Inflammatory Agents, Non-Steroidal, Pain, Fever. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National Key R&D Program of China, Taishan Scholar Program of Shandong Province, Distinguished Young and Middle-aged Scholar of Shandong University.
Abstract (Originalsprache)
Ibuprofen is a commonly used nonsteroidal anti‐inflammatory drug, and its injectable form has specific clinical applications. However, ibuprofen injection has not been approved for use in Chinese children. This study aimed to support its approval in this population using a model‐informed drug development (MIDD) approach. Ibuprofen injection (Fenliping®) received approval for Chinese pediatric indications in 2019, with a clinical trial waiver based on pediatric extrapolation using modeling and simulation. A physiologically based pharmacokinetic (PBPK) model was used to assess ethnic differences and determine the optimal dose for Chinese children. A single‐arm, open‐label trial was conducted in 40 pediatric patients aged 0.5–6 years to confirm the appropriateness of the 10 mg/kg dose. Body temperature, pain scores, and adverse events were collected to evaluate efficacy, safety, tolerability, and were used as clinical endpoints for exposure–response analysis. Sparse sampling was applied for pharmacokinetic analysis. A population pharmacokinetic (PopPK) model was developed using clinical data and used to refine the PBPK model and compare pharmacokinetics between Chinese and Caucasian children. Exposure–response analysis evaluated the relationship between exposure and clinical outcomes. The PBPK model showed minimal ethnic impact on pharmacokinetics, supporting a 10 mg/kg dose. In febrile patients, 89.5% achieved temperature < 38.5°C within 4 hours. Pain scores decreased below threshold. One mild drug‐related adverse event occurred. PK parameters were comparable across ethnicities, and no exposure–response relationship was observed. The MIDD approach supported full approval of ibuprofen injection in Chinese children. A 10 mg/kg dose was effective, safe, and well‐tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Pediatric Drug Clinical Evaluation and R&D Research Center of Engin…
- Chengdu Easton Biopharmaceuticals Co., Ltd, Chengdu, China.
- Department of Clinical Pharmacy, Institute of Clinical Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, School of Pha…
- Department of Pharmacy, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
- Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Di…
ORCID-Profile: Wei Zhao
Förderung
- National Key R&D Program of China
- Taishan Scholar Program of Shandong Province
- Distinguished Young and Middle-aged Scholar of Shandong University
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Lou, Q., Zhou, H., Wang, Z., Cao, J., Tang, B., Zheng, Y., Wang, Y., Bai, X., van den Anker, J., Hao, G., Liu, E., & Zhao, W. (2026). Model‐Informed Drug Development Supports Full Approval of Ibuprofen Injection in Chinese Pediatric Patients With Fever or Pain. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70143
Vancouver
Lou Q, Zhou H, Wang Z, Cao J, Tang B, Zheng Y, et al. Model‐Informed Drug Development Supports Full Approval of Ibuprofen Injection in Chinese Pediatric Patients With Fever or Pain. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70143
BibTeX
@article{Lou2026,
author = {Lou, Qianxi and Zhou, Haiyan and Wang, Zhuokang and Cao, Jing and Tang, Bohao and Zheng, Yi and Wang, Ying and Bai, Xiaowei and van den Anker, John and Hao, Guoxiang and Liu, Enmei and Zhao, Wei},
title = {Model‐Informed Drug Development Supports Full Approval of Ibuprofen Injection in Chinese Pediatric Patients With Fever or Pain},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70143}
}
EUVIMED